Affinity Asset Advisors, LLC and its managing member Michael Cho filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 1,850,000 shares of Jasper Therapeutics, Inc. Voting Common Stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Affinity Asset Advisors, LLC and Michael Cho each report beneficial ownership of 1,850,000 shares of Jasper Therapeutics Voting Common Stock, par value $0.0001 per share.
  • Percent of class: The 1,850,000 shares represent approximately 5.6% of the Common Stock outstanding as of September 30, 2026.
  • Shares outstanding basis: The percentage is calculated using 33,274,561 shares outstanding as of September 28, 2026, as set forth in the issuer's Definitive Proxy Statement filed October 19, 2026.
  • Voting and dispositive power: Both reporting persons report sole voting power and sole dispositive power over all 1,850,000 shares, with zero shared voting or dispositive power.
  • Direct holder: The securities are directly held by Affinity Healthcare Fund, LP; Affinity Asset Advisors, LLC serves as the fund's investment manager, and Michael Cho is the managing member of the Adviser.

Affinity Asset Advisors and Michael Cho Cross 5% Threshold in Jasper Therapeutics

According to the Schedule 13G filed November 13, 2026, with the triggering event dated September 30, 2026, Affinity Asset Advisors, LLC and Michael Cho are the two reporting persons disclosing a combined beneficial ownership position in Jasper Therapeutics, Inc. (NASDAQ:JSPR). The filing identifies the securities as Voting Common Stock with CUSIP number 471871202. Affinity Asset Advisors, LLC is organized as a Delaware limited liability company, and Michael Cho is identified as a U.S. citizen and the managing member of the Adviser.

The filing states that the securities are directly held by Affinity Healthcare Fund, LP. Affinity Asset Advisors, LLC, as investment manager of the fund, exercises voting and investment power over the securities pursuant to an investment management agreement between the Adviser, the fund, and the fund's general partner. As a result, the Adviser "may be deemed to beneficially own the securities reported herein held by the Fund by virtue of its position as investment manager of the Fund," according to the filing. Michael Cho, as managing member of the Adviser, "may be deemed a beneficial owner" of those same shares.

As of September 30, 2026, the reporting persons hold sole voting power and sole dispositive power over 1,850,000 shares, with no shared voting or dispositive power reported. The filing certifies, in accordance with Schedule 13G requirements, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed by Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer of Affinity Asset Advisors, LLC, and by Michael Cho, each on November 13, 2026.

What Was Disclosed

Affinity Asset Advisors, LLC and Michael Cho disclosed beneficial ownership of 1,850,000 shares of Jasper Therapeutics Voting Common Stock, equal to approximately 5.6% of outstanding shares as of September 30, 2026, held directly through Affinity Healthcare Fund, LP.